Somerville Kurt F Sells 11,898 Shares of Gilead Sciences (NASDAQ:GILD)

Somerville Kurt F decreased its holdings in Gilead Sciences (NASDAQ:GILD) by 39.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 18,219 shares of the biopharmaceutical company’s stock after selling 11,898 shares during the quarter. Somerville Kurt F’s holdings in Gilead Sciences were worth $1,304,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Gilead Sciences by 1.0% during the second quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock valued at $1,027,436,000 after buying an additional 136,884 shares in the last quarter. Aberdeen Asset Management PLC UK raised its stake in Gilead Sciences by 9.3% during the second quarter. Aberdeen Asset Management PLC UK now owns 2,057,324 shares of the biopharmaceutical company’s stock valued at $145,617,000 after buying an additional 175,102 shares in the last quarter. Skba Capital Management LLC raised its stake in Gilead Sciences by 33.7% during the second quarter. Skba Capital Management LLC now owns 142,500 shares of the biopharmaceutical company’s stock valued at $10,086,000 after buying an additional 35,900 shares in the last quarter. Johnson Financial Group Inc. raised its stake in Gilead Sciences by 34.1% during the second quarter. Johnson Financial Group Inc. now owns 46,280 shares of the biopharmaceutical company’s stock valued at $3,276,000 after buying an additional 11,768 shares in the last quarter. Finally, Vantage Investment Advisors LLC raised its stake in Gilead Sciences by 6.4% during the second quarter. Vantage Investment Advisors LLC now owns 3,937 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 236 shares in the last quarter. Institutional investors and hedge funds own 77.91% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $73.14, for a total transaction of $3,657,000.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $224,376,112.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 30,000 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total value of $2,370,000.00. Following the sale, the executive vice president now owns 57,114 shares of the company’s stock, valued at approximately $4,512,006. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 426,934 shares of company stock valued at $33,847,101. 1.30% of the stock is currently owned by corporate insiders.

Several brokerages have issued reports on GILD. Barclays restated an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Royal Bank of Canada reiterated a “buy” rating and set a $94.00 price target on shares of Gilead Sciences in a research report on Friday, February 23rd. Finally, Leerink Swann reiterated a “market perform” rating and set a $80.00 price target (down from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $88.61.

GILD stock traded down $1.41 on Friday, reaching $73.41. The company’s stock had a trading volume of 6,439,529 shares, compared to its average volume of 6,802,121. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54. The firm has a market capitalization of $97,554.05, a price-to-earnings ratio of 8.58, a price-to-earnings-growth ratio of -1.72 and a beta of 1.19. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% on a year-over-year basis. During the same period last year, the company posted $2.70 EPS. equities analysts anticipate that Gilead Sciences will post 6.21 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were paid a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

WARNING: “Somerville Kurt F Sells 11,898 Shares of Gilead Sciences (NASDAQ:GILD)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/somerville-kurt-f-trims-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply